MarketBeat
07 Nov 2026, 07:18 UTC · 53m ago
Elanco Animal Health Q3 Earnings Call Highlights
Impact · against what's priced in
Elanco is a positive catalyst due to a guidance raise and strong execution in its pet health portfolio, specifically Zenrelia and Credelio Quattro. While the loss of the Costco partnership creates a Q1 2027 headwind, the company's ability to exceed Q3 expectations and accelerate debt reduction provides immediate fundamental support.
- ELAN+0.70
No priced-in read yet
- In context
The company raised its 2026 revenue guidance to $5.155B–$5.18B and adjusted EPS to $1.17–$1.20, supported by record U.S. market share for Zenrelia and Credelio Quattro.
Read from the article alone
